Form 8-K - Current report:
SEC Accession No. 0001104659-26-032763
Filing Date
2026-03-20
Accepted
2026-03-20 16:43:52
Documents
17
Period of Report
2026-03-17
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm269428d1_8k.htm   iXBRL 8-K 39773
2 EXHIBIT 3.1 tm269428d1_ex3-1.htm EX-3.1 7449
3 EXHIBIT 3.2 tm269428d1_ex3-2.htm EX-3.2 36952
4 EXHIBIT 3.3 tm269428d1_ex3-3.htm EX-3.3 443617
8 GRAPHIC tm269428d1_ex3-1img01.jpg GRAPHIC 3560
9 GRAPHIC tm269428d1_ex3-1img02.jpg GRAPHIC 7911
10 GRAPHIC tm269428d1_ex3-2img01.jpg GRAPHIC 5089
  Complete submission text file 0001104659-26-032763.txt   782449

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA oncy-20260317.xsd EX-101.SCH 3041
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE oncy-20260317_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oncy-20260317_pre.xml EX-101.PRE 22376
20 EXTRACTED XBRL INSTANCE DOCUMENT tm269428d1_8k_htm.xml XML 3333
Mailing Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada
Business Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada 4036707377
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38512 | Film No.: 26778800
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)